Exelixis, Inc. (NASDAQ:EXEL) reported financial results for the fourth quarter and full year of 2016 and provided an update on progress toward delivering …
Exelixis, Inc. (NASDAQ:EXEL) announced a new collaboration with Roche on a phase 1b dose escalation study that will evaluate the safety and tolerability …
Exelixis, Inc. (NASDAQ:EXEL) and Takeda Pharmaceutical announced an exclusive licensing agreement for the commercialization and further clinical development in Japan of cabozantinib, Exelixis’ …
As he previews fourth-quarter results for these two biotech giants, William Blair analyst John Sonnier is setting positive expectations on Gilead Sciences, Inc. (NASDAQ:GILD) …
As earnings season rolls to the foreground and key biotech players like Gilead Sciences, Inc. (NASDAQ:GILD), Merrimack Pharmaceuticals Inc (NASDAQ:MACK), ACADIA Pharmaceuticals Inc.
Exelixis, Inc. (NASDAQ: EXEL) announced that Genentech, Inc.
Exelixis, Inc. (NASDAQ:EXEL) and Ipsen announced an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development of cabozantinib, to …
Exelixis, Inc. (NASDAQ:EXEL) announced two high-level appointments designed to further strengthen the company’s public affairs and business development capabilities following the launch of …
Insiders sell stock to diversify assets and is highly regulated and scrutinized. Insiders can only sell shares at certain times during the year, and …
Exelixis, Inc. (NASDAQ:EXEL) just announced a clinical update from ongoing trials evaluating its pipeline drug Cotellic (cobimetinib), the biotech firm-created MEK inhibitor that …
